Text Size

Treatment of Post Traumatic Stress Disorder in Patients With Other Mental Illnesses

This study has been completed.
Sponsor:
Information provided by:
National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:
NCT00053690
First received: February 4, 2003
Last updated: February 19, 2009
Last verified: February 2009
History of Changes
  Purpose

The purpose of this study is to develop an effective treatment for people with Post Traumatic Stress Disorder (PTSD) along with other mental illnesses.


Condition Intervention
Stress Disorders, Post-Traumatic
 Behavioral: Cognitive Behavior Treatment

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Cognitive-Behavioral Treatment of PTSD in SMI Clients

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute of Mental Health (NIMH):

Estimated Enrollment: 88
Study Start Date: January 2002
Estimated Study Completion Date: December 2004
Detailed Description:

Despite the progress in treating PTSD in the general population and the elevated prevalence of PTSD in people with severe mental illness (SMI), there are no empirically validated treatments designed for patients with comorbid PTSD. The cognitive behavioral treatment provided in this study may improve knowledge of PTSD, decrease distorted beliefs, reduce PTSD symptoms, and improve quality of life.

Participants are randomly assigned to receive either a cognitive behavioral treatment plus standard care for SMI or standard care alone. The cognitive behavioral treatment incorporates several common features, including psychoeducation, relaxation training, and cognitive restructuring. Standard care for SMI includes medication, case management, and psychosocial treatment. PTSD, psychiatric symptoms, health, quality of life, and substance abuse outcomes are measured. Participants' knowledge of PTSD and beliefs about the world are also measured. Participants are assessed at baseline, post-treatment (16 weeks), and at 3- and 6-month follow-ups.

For information on a related study, please follow this link:

http://clinicaltrials.gov/show/NCT00494650

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Post Traumatic Stress Disorder
  • New Hampshire definition of SMI plus DSM-IV Axis I diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depression
  • Case management services and contact with a case manager at least twice a week

Exclusion Criteria:

  • Alcohol or drug dependence
  • Hospitalization or suicide attempt in the past 2 months
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00053690

Locations
United States, New Hampshire
Community Mental Health Centers in NH
Claremont, New Hampshire, United States, 03301
Sponsors and Collaborators
National Institute of Mental Health (NIMH)
Investigators
Principal Investigator: Kim Mueser, Ph.D. Dartmouth-Hitchcock Medical Center
Principal Investigator: Stanley Rosenberg, Ph.D. Dartmouth-Hitchcock Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00053690     History of Changes
Other Study ID Numbers: R01 MH064662-01, DSIR AT-SP
Study First Received: February 4, 2003
Last Updated: February 19, 2009
Health Authority: United States: Federal Government

Keywords provided by National Institute of Mental Health (NIMH):
Comorbidity
Schizophrenia
Bipolar Disorder
Depression

Additional relevant MeSH terms:
Stress Disorders, Post-Traumatic
Stress Disorders, Traumatic
Anxiety Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 19, 2013